VEGF in the Crosstalk between Human Adipocytes and Smooth Muscle Cells: Depot-Specific Release from Visceral and Perivascular Adipose Tissue
Figure 4
VEGF release is higher from PAT of type 2 diabetic patients correlating with VSMC proliferation and VEGF-R1/2 expression. (a) VEGF content of CM from PAT and SAT was measured in duplicates by ELISA. (b) VSMC were treated with CM from paired SAT and PAT of patients with type 2 diabetes (Diab) and nondiabetics controls (ND) for 24 h. The proliferation was determined by measuring the incorporation of BrdU into DNA. Data are expressed relative to the basal control value, which was set as 100%. Data are presented as mean ± SEM from five independent experiments. (c–e) Total cell lysates were resolved by SDS-PAGE and immunoblotted with specific VEGF-R1 and 2 antibodies. Data are mean values ± SEM of three to five independent experiments. All data were normalized to the level of actin expression and are expressed relative to the control. * compared to control or designated data.
